Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1998-11-04
2000-01-18
Owens, Amelia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
560119, 549292, 514824, A61K 31225, C07C 6974
Patent
active
RE0365203
ABSTRACT:
Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are useful as antihypercholesterolemic agents and are represented by the following general structural formula (II): ##STR1##
REFERENCES:
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4294846 (1981-10-01), Albers-Schonberg et al.
patent: 4351844 (1982-09-01), Patchett et al.
patent: 4361515 (1982-11-01), Terahara et al.
patent: 4376863 (1983-03-01), Lam
patent: 4444784 (1984-04-01), Hoffman et al.
patent: 4448979 (1984-05-01), Terahara et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4517373 (1985-05-01), Terahara et al.
patent: 4537859 (1985-08-01), Terahara et al.
patent: 4661483 (1987-04-01), Hoffman et al.
patent: 4668699 (1987-05-01), Hoffman et al.
patent: 4766145 (1988-08-01), Lee et al.
patent: 4795811 (1989-01-01), Graham et al.
patent: 4831165 (1989-05-01), De Camp et al.
patent: 4841074 (1989-06-01), Lee et al.
patent: 4847306 (1989-07-01), Lee et al.
patent: 4855456 (1989-08-01), Lee et al.
patent: 4857546 (1989-08-01), Duggan et al.
patent: 4857547 (1989-08-01), Hoffman et al.
patent: 4876364 (1989-10-01), Schuda et al.
patent: 4894465 (1990-01-01), Lee et al.
patent: 4894466 (1990-01-01), Lee et al.
patent: 4916162 (1990-04-01), Hoffman et al.
patent: 4937263 (1990-06-01), Hoffman et al.
patent: 4946864 (1990-08-01), Prugh et al.
patent: 4997755 (1991-03-01), Williamson et al.
Stokker et al, J. Med Chem., 1985, 28 pp. 347-358, 1985.
Heller Shrewsbury, J. Biol. Chem., 1976, 251 pp. 3815-3822, 1976.
Kleinsek et al., Proc. Nat'l Acad Sci, USA, 1977, 74, pp. 1431-1435, 1977.
Shefer et al, J. Lipid Res., 1972, 13, pp. 402-412 1972.
Sugiyama et al, CA 111:120925 n, 1989.
Rosenthal et al, J. Am. Chem Soc, 1959, 80 pp. 5240-5241, 1959.
A. G. Olsson et al., "Synvinolin in Hypercholesterolaemia", The Lancet, pp. 390-391 Aug. 16, 1986.
P. Weisweiler et al., "Colestipol Plus Fenofibrate Versus Synvinolin in Familial Hypercholesterolaemia", The Lancet, pp. 1212-1213, Nov. 22, 1986.
A.F. Stalenhoef et al., "Effect of Synvinolin, a New Cholestrol Synthesis Inhibitor, in Familial Hypercholesterolemia", Arteriosclerosis , vol. 6, No. 5, Sep./Oct. 1986.
M.J.T.M. Mol. et al., "Effects of Synvinolin (MK-733) On Plasma Lipids in Familial Hypercholesterolaemia", The Lancet, pp. 936-939, Oct. 25, 1986.
S. M. Grundy et al., "Effects of Mevinolin on Plasma Lipoprotein (LP) Matabolism in Moderate Hypercholesterolaemia", Abstracts Circulation , vol. 70, Supp. II p. 268, No. 1072 (1984).
D. W. Bilheimer et al., "Mevinilin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes", Proc. Natl. Acad. Sci. USA, vol. 80 pp. 4124-4128 (Jul. 1983).
D. W. Bilheimer et al., "Mevinolin Stimulates Receptor-Mediated Clearance of LDL in Familial Hypercholesterolemia (FH) Heterozygotes", Clin. Res. 31, No. 2, p. 544A (1983).
J. A. Tobert et al., Cholesterol-lowering effect of Mevinolin, an Inhibitor of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase, in Healthy Volunteers, J. Clin Invest. (USA), 69 (4), pp. 913-919 (Apr. 1982).
J. A. Tobert et al., "Rapid and Substantial Loweing of Human Serum Cholestrol by Mevinolin (MK-803), An Inhibitor of Hydroxymethylglutaryl-Coenzyme A Reductase", Atherosclerosis, 41, pp. 61-65 (1982).
Halczenko Wasyl
Hartman George D.
Hensens Otto D.
Houck David R.
Inamine Edward S.
Merck & Co. , Inc.
Owens Amelia
Quagliato Carol S.
Winokur Melvin
LandOfFree
HMG-CoA reductase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HMG-CoA reductase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HMG-CoA reductase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-556603